Ionis lowered its 2026 Tringolza net product sales guidance to approximately $50 million, citing a more gradual launch ramp. It kept total revenue guidance at $875 million to $900 million and now expects cash flow break-even in 2029.
IONS · Ionis Pharmaceuticals Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Ionis Pharmaceuticals reported nine-month 2026 revenue of $756.8 million, up from $740.4 million, while net loss widened to $317.1 million from $152.0 million. Eplontersen and pelacarsen Phase 3 trials missed primary endpoints; ulefnersen and sefaxersen reported positive Phase 3 results.
Ionis Pharmaceuticals lowered TRYNGOLZA 2026 product sales guidance to ~$50 million from $100-110 million after a more gradual launch ramp, while reaffirming 2026 total revenue guidance of $875-900 million.
Ionis Pharmaceuticals said Roche’s Phase 3 IMAgINATION data showed investigational sefaxersen reduced proteinuria by 43.1% versus placebo at 37 weeks, with greater hematuria resolution and no new safety signals.
FDA approved GSK’s HIBSAGO™ (bepirovirsen) for specified adults with chronic hepatitis B; Phase 3 B-Well trials showed 19% functional cure, and Ionis Pharmaceuticals Inc is eligible for tiered royalties of 10-12% on net sales.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
AI Brief
Q3 FY26 earnings call · Nov 9, 2026TL;DR. Ionis reported revenue growth of 55% in Q3 excluding a one-time 2025 payment and reaffirmed its total revenue guidance. However, it cut TRYNGOLZA 2026 product sales guidance to about $50 million and shifted cash-flow break-even to 2029 from 2028.
- + Total revenue rose 55% in Q3 and 64% for nine months, excluding a one-time 2025 payment. new
- + DAWNZERA generated $37 million of U.S. net product sales in Q3 and continues to gain momentum. new
- + Total R&D revenue rose to $107 million in Q3 from $41 million a year earlier. new
- + ZANVASTRO's first patients have received commercial treatment after launch. new
- + Hibsago approved in the U.S. and Japan for chronic hepatitis B. new
- + Total 2026 revenue guidance of $875-900 million is reaffirmed. new
- − TRYNGOLZA 2026 product sales guidance cut to about $50 million from $100-110 million. new
- − CARDIO-TTRansform missed its primary composite endpoint in the overall population.
- − Cash fell to $1.9 billion from $2.7 billion at year-end 2025. new
- − Cash-flow break-even timing shifted to 2029 from 2028. new
- − A majority of TRYNGOLZA prescriptions required a medical exception early in the launch. new
- − Two recent Phase 3 readouts did not deliver the outcomes management hoped for. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IONS
this stock
Ionis Pharmaceuticals Inc
|
$4.49B | -65.9% | +46.5% | — | 12.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$135.44B | +17.8% | +46.2% | 34.4 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$99.08B | +24.1% | +20.8% | 21.2 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.68B | +601.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$64.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 9, 2026
- This year
- 31
Ionis Pharmaceuticals lowered TRYNGOLZA 2026 product sales guidance to ~$50 million from $100-110 million after a more gradual launch ramp, while reaffirming 2026 total revenue guidance of $875-900 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IONS | -4.4% | -40.6% | -65.1% | -38.1% | -65.9% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | -2.0% | -35.9% | -62.2% | -35.0% | -73.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.